Related Experiment Videos
[Retrospective estimation of immune status in children with acute hematogenic osteomyelitis]
Insights
Estimating immune status in children with acute gematogenic osteomyelitis helps predict disease duration and guide treatment. Slow immune responses indicate disease severity and complications, necessitating timely therapeutic adjustments.
Area of Science:
- Pediatric Infectious Diseases
- Immunology
- Orthopedic Surgery
Context:
- Acute gematogenic osteomyelitis affects children, posing challenges in prognosis and treatment.
- Assessing the immune state is crucial for managing this condition.
- Understanding immune response variations aids in clinical decision-making.
Purpose:
- To estimate the immune state in children with acute gematogenic osteomyelitis.
- To correlate immune status with disease course duration and treatment outcomes.
- To inform treatment tactics based on immunologic data.
Summary:
- Immune state estimation was performed in 45 children with acute gematogenic osteomyelitis.
- Two treatment duration groups (≤40 days and 41–160 days) were identified.
- Immunologic data successfully predicted disease course and allowed for timely treatment correction.
- Slow immune reactions were linked to disease severity and complications.
Impact:
- Provides a method for prognostication in pediatric osteomyelitis.
- Enables personalized treatment strategies based on individual immune responses.
- Highlights the role of immune status in disease severity and recovery.
- Contributes to improved management of acute gematogenic osteomyelitis in children.
Abstract:
The immune state estimation in 45 children with an acute gematogenic osteomyelitis was done for the disease course prognosis and the treatment tactic choice. Two groups with duration of treatment up to forty days and from 41 to 160 days were delineated. The immunologic investigation data permitted to prognosticate the disease course duration and to correct the treatment timely. Slow immune reaction of organism in patients was caused by the disease severity and presence of complications.